<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-204-8-123-132</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2138</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL PHARMACOLOGY</subject></subj-group></article-categories><title-group><article-title>Синдром повышенной эпителиальной проницаемости: возможности современной фармакотерапии</article-title><trans-title-group xml:lang="en"><trans-title>Syndrome of increased epithelial permeability: opportunities of current pharmacotherapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8844-2465</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Туркина</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Turkina</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">turkina.vlg@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3306-0312</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стаценко</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Statsenko</surname><given-names>M. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3046-7264</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тыщенко</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tyshchenko</surname><given-names>I. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>18</day><month>01</month><year>2023</year></pub-date><volume>0</volume><issue>8</issue><fpage>123</fpage><lpage>132</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Туркина С.В., Стаценко М.Е., Тыщенко И.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Туркина С.В., Стаценко М.Е., Тыщенко И.А.</copyright-holder><copyright-holder xml:lang="en">Turkina S.V., Statsenko M.E., Tyshchenko I.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2138">https://www.nogr.org/jour/article/view/2138</self-uri><abstract><p>Синдром повышенной эпителиальной проницаемости (СПЭП) рассматривается как один из универсальных механизмов, обуславливающий последующее развитие хронического системного воспаления разной степени выраженности. Проведенные в последние 10 лет исследования показали важную роль СПЭП в патогенезе многих заболеваний внутренних органов, и, прежде всего, желудочно-кишечного тракта (ЖКТ). В статье обсуждаются возможные пути коррекции нарушения эпителиальной проницаемости с точки зрения цитопротекторных эффектов препаратов, наиболее часто назначаемых пациентам гастроэнтерологического профиля.</p></abstract><trans-abstract xml:lang="en"><p>Syndrome of increased epithelial permeability (SPEP) is considered as one of the universal mechanisms that determine the subsequent development of chronic systemic inflammation of varying severity. Studies carried out in the last 10 years have shown the important role of SPEP in the pathogenesis of many diseases of internal organs, and, first of all, of the gastrointestinal diseases. The article discusses possible ways of correcting impaired epithelial permeability from the point of view of the cytoprotective effects of drugs most often prescribed to patients with gastrontestinal diseases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром повышенной эпителиальной проницаемости</kwd><kwd>цитопротекция</kwd><kwd>ингибиторы протоновой помпы</kwd><kwd>препараты висмута</kwd><kwd>пробиотики</kwd><kwd>ребамипид</kwd></kwd-group><kwd-group xml:lang="en"><kwd>syndrome of increased epithelial permeability</kwd><kwd>cytoprotection</kwd><kwd>proton pump inhibitors</kwd><kwd>bismuth preparations</kwd><kwd>probiotics</kwd><kwd>rebamipide</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Simanenkov V. I., Maev I. V., Tkacheva O. N., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi: 10.15829/1728-8800-2021-2758.@@ Симаненков В. И., Маев И. В., Ткачева О. Н., и Соавт. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. doi: 10.15829/1728-8800-2021-2758.</mixed-citation><mixed-citation xml:lang="en">Simanenkov V. I., Maev I. V., Tkacheva O. N., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi: 10.15829/1728-8800-2021-2758.@@ Симаненков В. И., Маев И. В., Ткачева О. Н., и Соавт. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. doi: 10.15829/1728-8800-2021-2758.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Perveen I., Rahman M. M., Saha M., et al. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol. 2014;33(3):265-73. doi: 10.1007/s12664-014-0447-1.</mixed-citation><mixed-citation xml:lang="en">Perveen I., Rahman M. M., Saha M., et al. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol. 2014;33(3):265-73. doi: 10.1007/s12664-014-0447-1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Beeckmans D., Farré R., Riethorst D., et al. Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia. Neurogastroenterol Motil. 2020;32(5): e13788. doi: 10.1111/nmo.13788.</mixed-citation><mixed-citation xml:lang="en">Beeckmans D., Farré R., Riethorst D., et al. Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia. Neurogastroenterol Motil. 2020;32(5): e13788. doi: 10.1111/nmo.13788.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Singh P., Silvester J., Chen X., et al. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D. United European Gastroenterol J. 2019;7(5):709-15. doi: 10.1177/2050640619826419.</mixed-citation><mixed-citation xml:lang="en">Singh P., Silvester J., Chen X., et al. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D. United European Gastroenterol J. 2019;7(5):709-15. doi: 10.1177/2050640619826419.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Orlando L. A., Orlando R. C. Dilated intercellular spaces as a marker of GERD. Curr Gastroenterol Rep. 2009;11:190-4. doi: 10.1007/s11894-009-0030-6.</mixed-citation><mixed-citation xml:lang="en">Orlando L. A., Orlando R. C. Dilated intercellular spaces as a marker of GERD. Curr Gastroenterol Rep. 2009;11:190-4. doi: 10.1007/s11894-009-0030-6.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dang Y., Zhang Y., Xu L., et al. PUMA-mediated epithelial cell apoptosis promotes Helicobacter pylori infection-mediated gastritis. Cell Death Dis. 2020;11(2):139 doi: 10.1038/s41419-020-2339-x.</mixed-citation><mixed-citation xml:lang="en">Dang Y., Zhang Y., Xu L., et al. PUMA-mediated epithelial cell apoptosis promotes Helicobacter pylori infection-mediated gastritis. Cell Death Dis. 2020;11(2):139 doi: 10.1038/s41419-020-2339-x.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz L., López P., Suárez A., et al. The role of gut microbiota in lupus: what we know in 2018? Expert Rev Clin Immunol. 2018;14(10):787-92. doi: 10.1080/1744666X.2018.1519395.</mixed-citation><mixed-citation xml:lang="en">Ruiz L., López P., Suárez A., et al. The role of gut microbiota in lupus: what we know in 2018? Expert Rev Clin Immunol. 2018;14(10):787-92. doi: 10.1080/1744666X.2018.1519395.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sandek A., Bjarnason I., Volk H. D., et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure.Int J Cardiol. 2012;157(1):80-5. doi: 10.1016/j. ijcard.2010.12.016.</mixed-citation><mixed-citation xml:lang="en">Sandek A., Bjarnason I., Volk H. D., et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure.Int J Cardiol. 2012;157(1):80-5. doi: 10.1016/j. ijcard.2010.12.016.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sweerus K., Lachowicz-Scroggins M., Gordon E., et al. Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma. J Allergy Clin Immunol. 2017;139(1):72-81.e1. doi: 10.1016/j.jaci.2016.02.035.</mixed-citation><mixed-citation xml:lang="en">Sweerus K., Lachowicz-Scroggins M., Gordon E., et al. Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma. J Allergy Clin Immunol. 2017;139(1):72-81.e1. doi: 10.1016/j.jaci.2016.02.035.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Keely S., Talley N. J., Hansbro P. M. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012;5:7-18. doi: 10.1038/mi.2011.55.</mixed-citation><mixed-citation xml:lang="en">Keely S., Talley N. J., Hansbro P. M. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012;5:7-18. doi: 10.1038/mi.2011.55.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hurst R. E., Greenwood-Van Meerveld B., Wisniewski A. B., et al. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. Transl Androl Urol. 2015;4(5):563-71. doi: 10.3978/j.issn.2223-4683.2015.10.03.</mixed-citation><mixed-citation xml:lang="en">Hurst R. E., Greenwood-Van Meerveld B., Wisniewski A. B., et al. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. Transl Androl Urol. 2015;4(5):563-71. doi: 10.3978/j.issn.2223-4683.2015.10.03.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou N., Shen Y., Fan L., et al. The Characteristics of Intestinal Barrier Damage in Rats With IgA Nephropathy. Am J Med Sci. 2020;359(3):168-76. doi: 10.1016/j.amjms.2019.11.011.</mixed-citation><mixed-citation xml:lang="en">Zhou N., Shen Y., Fan L., et al. The Characteristics of Intestinal Barrier Damage in Rats With IgA Nephropathy. Am J Med Sci. 2020;359(3):168-76. doi: 10.1016/j.amjms.2019.11.011.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Welcome M. O. Cellular mechanisms and molecular signaling pathways in stress-induced anxiety, depression, and bloodbrain barrier inflammation and leakage. Inflammopharmacology. 2020;28(3):643-65. doi: 10.1007/s10787-020-00712-8.</mixed-citation><mixed-citation xml:lang="en">Welcome M. O. Cellular mechanisms and molecular signaling pathways in stress-induced anxiety, depression, and bloodbrain barrier inflammation and leakage. Inflammopharmacology. 2020;28(3):643-65. doi: 10.1007/s10787-020-00712-8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ho S. B., Takamura K., Anway R., Shekels L. L., Toribara N. W., Ota H. The adherent gastric mucous layer is composed of alternating layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci. 2004 Oct;49(10):1598-606. doi: 10.1023/b: ddas.0000043371.12671.98.</mixed-citation><mixed-citation xml:lang="en">Ho S. B., Takamura K., Anway R., Shekels L. L., Toribara N. W., Ota H. The adherent gastric mucous layer is composed of alternating layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci. 2004 Oct;49(10):1598-606. doi: 10.1023/b: ddas.0000043371.12671.98.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Niv Y. Helicobacter pylori and gastric mucin expression: A systematic review and meta-analysis. World J Gastroenterol. 2015;21(31):9430-9436. doi: 10.3748/wjg.v21.i31.9430.</mixed-citation><mixed-citation xml:lang="en">Niv Y. Helicobacter pylori and gastric mucin expression: A systematic review and meta-analysis. World J Gastroenterol. 2015;21(31):9430-9436. doi: 10.3748/wjg.v21.i31.9430.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yandrapu H., Sarosiek J. Protective Factors of the Gastric and Duodenal Mucosa: An Overview. Curr Gastroenterol Rep. 2015 Jun;17(6):24. doi: 10.1007/s11894-015-0452-2.</mixed-citation><mixed-citation xml:lang="en">Yandrapu H., Sarosiek J. Protective Factors of the Gastric and Duodenal Mucosa: An Overview. Curr Gastroenterol Rep. 2015 Jun;17(6):24. doi: 10.1007/s11894-015-0452-2.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Samsonov А. А., Golubev N. N., Andreev N. G., Shcherbakova N. A. The protective barrier of the gastric mucosa and the possibility of drug cytoprotection. Handbook for Practitioners Doctors. 2018; 6: 40-48. (In Russ.)@@ Самсонов А. А., Голубев Н. Н., Андреев Н. Г., Щербакова Н. А. Защитный барьер слизистой оболочки желудка и возможности лекарственной цитопротекции. Справочник поликлинического врача. 2018; 6: 40-48.</mixed-citation><mixed-citation xml:lang="en">Samsonov А. А., Golubev N. N., Andreev N. G., Shcherbakova N. A. The protective barrier of the gastric mucosa and the possibility of drug cytoprotection. Handbook for Practitioners Doctors. 2018; 6: 40-48. (In Russ.)@@ Самсонов А. А., Голубев Н. Н., Андреев Н. Г., Щербакова Н. А. Защитный барьер слизистой оболочки желудка и возможности лекарственной цитопротекции. Справочник поликлинического врача. 2018; 6: 40-48.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Komuro Y., Ishii K., Miyake Y., Tanabe S., Oida M., Saigenji K. Effects of lansoprazole on gastric ulcer healing and mucin content. J Clin Gastroenterol. 1995;20 Suppl 2: S47-51. doi: 10.1097/00004836-199506002-00013.</mixed-citation><mixed-citation xml:lang="en">Komuro Y., Ishii K., Miyake Y., Tanabe S., Oida M., Saigenji K. Effects of lansoprazole on gastric ulcer healing and mucin content. J Clin Gastroenterol. 1995;20 Suppl 2: S47-51. doi: 10.1097/00004836-199506002-00013.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshimura K., Delbarre S. G., Kraus E., Boland C. R. The effects of omeprazole and famotidine on mucin and PGE2 release in the rat stomach. Aliment Pharmacol Ther. 1996 Feb;10(1):111-7. doi: 10.1111/j.1365-2036.1996.tb00184.x.</mixed-citation><mixed-citation xml:lang="en">Yoshimura K., Delbarre S. G., Kraus E., Boland C. R. The effects of omeprazole and famotidine on mucin and PGE2 release in the rat stomach. Aliment Pharmacol Ther. 1996 Feb;10(1):111-7. doi: 10.1111/j.1365-2036.1996.tb00184.x.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Jaworski T., Sarosiek I., Sostarich S., Roeser K., Connor M., Brotze S., Wallner G., Sarosiek J. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50(2):357-65. doi: 10.1007/s10620-005-1611-3.</mixed-citation><mixed-citation xml:lang="en">Jaworski T., Sarosiek I., Sostarich S., Roeser K., Connor M., Brotze S., Wallner G., Sarosiek J. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50(2):357-65. doi: 10.1007/s10620-005-1611-3.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ford A. C., Malfertheiner P., Giguere M., et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14(48):7361-70. doi: 10.3748/wjg.14.7361.</mixed-citation><mixed-citation xml:lang="en">Ford A. C., Malfertheiner P., Giguere M., et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14(48):7361-70. doi: 10.3748/wjg.14.7361.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Schanova N. O., Prokhorova L. V. Improvement of Helicobacter pylori eradication efficacy at stomach and duodenum peptic ulcers.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):11-18. (In Russ.) doi: 10.22416/1382-4376-2016-26-2-11-18.@@ Щанова Н. О., Прохорова Л. В. Возможности повышения эффективности эрадикации Helicobacter pylori у больных язвенной болезнью желудка и двенадцатиперстной кишки. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2):11-18. doi: 10.22416/1382-4376-2016-26-2-11-18.</mixed-citation><mixed-citation xml:lang="en">Schanova N. O., Prokhorova L. V. Improvement of Helicobacter pylori eradication efficacy at stomach and duodenum peptic ulcers.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):11-18. (In Russ.) doi: 10.22416/1382-4376-2016-26-2-11-18.@@ Щанова Н. О., Прохорова Л. В. Возможности повышения эффективности эрадикации Helicobacter pylori у больных язвенной болезнью желудка и двенадцатиперстной кишки. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2):11-18. doi: 10.22416/1382-4376-2016-26-2-11-18.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zakharova N., Savilova I. Efficacy of reinforced eradication therapy in region of high claritromycin resistance. Helicobacter 2015; 20(Suppl 1):92</mixed-citation><mixed-citation xml:lang="en">Zakharova N., Savilova I. Efficacy of reinforced eradication therapy in region of high claritromycin resistance. Helicobacter 2015; 20(Suppl 1):92</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. (In Russ.) doi: 10.22416/1382-4376-2018-28-1-55-70.@@ Ивашкин В. Т., Маев И. В., Лапина Т. Л., Шептулин А. А., и Соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70. doi: 10.22416/1382-4376-2018-28-1-55-70.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. (In Russ.) doi: 10.22416/1382-4376-2018-28-1-55-70.@@ Ивашкин В. Т., Маев И. В., Лапина Т. Л., Шептулин А. А., и Соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70. doi: 10.22416/1382-4376-2018-28-1-55-70.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">König J., Wells J., Cani P. D., García-Ródenas C.L., MacDonald T., Mercenier A., Whyte J., Troost F., Brummer R. J. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. 2016;20;7(10): e196. doi: 10.1038/ctg.2016.54.</mixed-citation><mixed-citation xml:lang="en">König J., Wells J., Cani P. D., García-Ródenas C.L., MacDonald T., Mercenier A., Whyte J., Troost F., Brummer R. J. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. 2016;20;7(10): e196. doi: 10.1038/ctg.2016.54.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mu Q., Kirby J., Reilly C. M., Luo X. M. Leaky Gut As a Danger Signal for Autoimmune Diseases. Front Immunol. 2017 May 23;8:598. doi:10.3389/fimmu.2017.00598.</mixed-citation><mixed-citation xml:lang="en">Mu Q., Kirby J., Reilly C. M., Luo X. M. Leaky Gut As a Danger Signal for Autoimmune Diseases. Front Immunol. 2017 May 23;8:598. doi:10.3389/fimmu.2017.00598.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Desai M. S., Seekatz A. M., Koropatkin N. M., Kamada N., Hickey C. A., Wolter M., et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 2016; 167(5):1339-53 e21. doi: 10.1016/j.cell.2016.10.043.</mixed-citation><mixed-citation xml:lang="en">Desai M. S., Seekatz A. M., Koropatkin N. M., Kamada N., Hickey C. A., Wolter M., et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 2016; 167(5):1339-53 e21. doi: 10.1016/j.cell.2016.10.043.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Johansson M. E., Jakobsson H. E., Holmen-Larsson J., Schutte A., Ermund A., Rodriguez-Pineiro A.M., et al. Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe 2015; 18(5):582-92. doi: 10.1016/j.chom.2015.10.007.</mixed-citation><mixed-citation xml:lang="en">Johansson M. E., Jakobsson H. E., Holmen-Larsson J., Schutte A., Ermund A., Rodriguez-Pineiro A.M., et al. Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe 2015; 18(5):582-92. doi: 10.1016/j.chom.2015.10.007.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Petersson J., Schreiber O., Hansson G. C., Gendler S. J., Velcich A., Lundberg J. O., et al. Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol. 2011; 300(2): G327-G333. doi: 10.1152/ajpgi.00422.2010.</mixed-citation><mixed-citation xml:lang="en">Petersson J., Schreiber O., Hansson G. C., Gendler S. J., Velcich A., Lundberg J. O., et al. Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol. 2011; 300(2): G327-G333. doi: 10.1152/ajpgi.00422.2010.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wrzosek L., Miquel S., Noordine M. L., Bouet S., Joncquel Chevalier-Curt M., Robert V., et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol 2013; 11:61. doi: 10.1186/1741-7007-11-61.</mixed-citation><mixed-citation xml:lang="en">Wrzosek L., Miquel S., Noordine M. L., Bouet S., Joncquel Chevalier-Curt M., Robert V., et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol 2013; 11:61. doi: 10.1186/1741-7007-11-61.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Forder R. E., Howarth G. S., Tivey D. R., Hughes R. J. Bacterial modulation of small intestinal goblet cells and mucin composition during early posthatch development of poultry. Poult Sci 2007; 86(11):2396-403. doi: 10.3382/ps.2007-00222.</mixed-citation><mixed-citation xml:lang="en">Forder R. E., Howarth G. S., Tivey D. R., Hughes R. J. Bacterial modulation of small intestinal goblet cells and mucin composition during early posthatch development of poultry. Poult Sci 2007; 86(11):2396-403. doi: 10.3382/ps.2007-00222.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Johansson M. E., Gustafsson J. K., Sjoberg K. E., Petersson J., Holm L., Sjovall H., et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One 2010; 5(8): e12238. doi: 10.1371/journal.pone.0012238.</mixed-citation><mixed-citation xml:lang="en">Johansson M. E., Gustafsson J. K., Sjoberg K. E., Petersson J., Holm L., Sjovall H., et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One 2010; 5(8): e12238. doi: 10.1371/journal.pone.0012238.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kaibysheva V. O., Zharova M. E., Filimendikova K. Yu., Nikonov E. L. Human Microbiome: age-related changes and functions.Russian Journal of Evidence-Based Gastroenterology. 2020;9(2):42-55. (In Russ.) doi: 10.17116/dokgastro2020902142.@@ Кайбышева В. О., Жарова М. Е., Филимендикова К. Ю., Никонов Е. Л. Микробиом человека: возрастные изменения и функции. Доказательная гастроэнтерология. 2020;9(2):42-55. doi: 10.17116/dokgastro2020902142.</mixed-citation><mixed-citation xml:lang="en">Kaibysheva V. O., Zharova M. E., Filimendikova K. Yu., Nikonov E. L. Human Microbiome: age-related changes and functions.Russian Journal of Evidence-Based Gastroenterology. 2020;9(2):42-55. (In Russ.) doi: 10.17116/dokgastro2020902142.@@ Кайбышева В. О., Жарова М. Е., Филимендикова К. Ю., Никонов Е. Л. Микробиом человека: возрастные изменения и функции. Доказательная гастроэнтерология. 2020;9(2):42-55. doi: 10.17116/dokgastro2020902142.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mandato C., Di Nuzzi A., Vajro P. Nutrition and Liver Disease. Nutrients. 2018;10(1):9. doi: 10.3390/nu10010009.</mixed-citation><mixed-citation xml:lang="en">Mandato C., Di Nuzzi A., Vajro P. Nutrition and Liver Disease. Nutrients. 2018;10(1):9. doi: 10.3390/nu10010009.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Albillos A., de Gottardi A., Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003.</mixed-citation><mixed-citation xml:lang="en">Albillos A., de Gottardi A., Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Madsen K., Cornish A., Soper P., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121(3):580-591. doi: 10.1053/gast.2001.27224.</mixed-citation><mixed-citation xml:lang="en">Madsen K., Cornish A., Soper P., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121(3):580-591. doi: 10.1053/gast.2001.27224.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Zareie M., Johnson-Henry K., Jury J., et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut. 2006;55(11):1553-1560. doi: 10.1136/gut.2005.080739.</mixed-citation><mixed-citation xml:lang="en">Zareie M., Johnson-Henry K., Jury J., et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut. 2006;55(11):1553-1560. doi: 10.1136/gut.2005.080739.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Zyrek A. A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M. A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 2007;9(3):804-816. doi: 10.1111/j.1462-5822.2006.00836.x.</mixed-citation><mixed-citation xml:lang="en">Zyrek A. A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M. A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 2007;9(3):804-816. doi: 10.1111/j.1462-5822.2006.00836.x.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Bron P. A., Kleerebezem M., Brummer R. J., et al. Can probiotics modulate human disease by impacting intestinal barrier function?. Br J Nutr. 2017;117(1):93-107. doi: 10.1017/S0007114516004037.</mixed-citation><mixed-citation xml:lang="en">Bron P. A., Kleerebezem M., Brummer R. J., et al. Can probiotics modulate human disease by impacting intestinal barrier function?. Br J Nutr. 2017;117(1):93-107. doi: 10.1017/S0007114516004037.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Gotteland M., Cruchet S., Verbeke S. Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Aliment Pharmacol Ther. 2001;15(1):11-17. doi: 10.1046/j.1365-2036.2001.00898.x.</mixed-citation><mixed-citation xml:lang="en">Gotteland M., Cruchet S., Verbeke S. Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Aliment Pharmacol Ther. 2001;15(1):11-17. doi: 10.1046/j.1365-2036.2001.00898.x.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Ghouri Y. A., Richards D. M., Rahimi E. F., Krill J. T., Jelinek K. A., DuPont A. W. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473-487. Published 2014 Dec 9. doi: 10.2147/CEG.S27530.</mixed-citation><mixed-citation xml:lang="en">Ghouri Y. A., Richards D. M., Rahimi E. F., Krill J. T., Jelinek K. A., DuPont A. W. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473-487. Published 2014 Dec 9. doi: 10.2147/CEG.S27530.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Ramezani Ahmadi A., Sadeghian M., Alipour M., Ahmadi Taheri S., Rahmani S., Abbasnezhad A. The Effects of Probiotic/Synbiotic on Serum Level of Zonulin as a Biomarker of Intestinal Permeability: A Systematic Review and Meta-Analysis. Iran J Public Health. 2020;49(7):1222-1231. doi: 10.18502/ijph.v49i7.3575.</mixed-citation><mixed-citation xml:lang="en">Ramezani Ahmadi A., Sadeghian M., Alipour M., Ahmadi Taheri S., Rahmani S., Abbasnezhad A. The Effects of Probiotic/Synbiotic on Serum Level of Zonulin as a Biomarker of Intestinal Permeability: A Systematic Review and Meta-Analysis. Iran J Public Health. 2020;49(7):1222-1231. doi: 10.18502/ijph.v49i7.3575.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Ivashkin V. T., Mayev I. V., Abdulganieva D. I., et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and Russian Gastroenterological Association (RGA) for Probiotics in Treatment and Prevention of Gastroenterological Diseases in Adults.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):76-89. (In Russ.) doi: 10.22416/1382-4376-2020-30-2-76-89.@@ Ивашкин В. Т., Маев И. В., Абдулганиева Д. И., и соавт. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков для лечения и профилактики заболеваний гастроэнтерологического профиля у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):76-89. doi: 10.22416/1382-4376-2020-30-2-76-89.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Mayev I. V., Abdulganieva D. I., et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and Russian Gastroenterological Association (RGA) for Probiotics in Treatment and Prevention of Gastroenterological Diseases in Adults.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):76-89. (In Russ.) doi: 10.22416/1382-4376-2020-30-2-76-89.@@ Ивашкин В. Т., Маев И. В., Абдулганиева Д. И., и соавт. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков для лечения и профилактики заболеваний гастроэнтерологического профиля у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):76-89. doi: 10.22416/1382-4376-2020-30-2-76-89.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">WGO Global Guideline Probiotics and prebiotics, 2017 URL: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics</mixed-citation><mixed-citation xml:lang="en">WGO Global Guideline Probiotics and prebiotics, 2017 URL: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Zvyaglova M. Yu., Knyazev O. V., Parfenov A. I. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Therapeutic Archive. 2020; 92 (2): 104-111. (In Russ) doi: 10.26442/00403660.2020.02.000569.@@ Звяглова М. Ю., Князев О. В., Парфенов А. И. Фармакологический и клинический профиль ребамипида: новые терапевтические мишени. Терапевтический архив. 2020; 92 (2): 104-111. doi: 10.26442/00403660.2020.02.000569.</mixed-citation><mixed-citation xml:lang="en">Zvyaglova M. Yu., Knyazev O. V., Parfenov A. I. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Therapeutic Archive. 2020; 92 (2): 104-111. (In Russ) doi: 10.26442/00403660.2020.02.000569.@@ Звяглова М. Ю., Князев О. В., Парфенов А. И. Фармакологический и клинический профиль ребамипида: новые терапевтические мишени. Терапевтический архив. 2020; 92 (2): 104-111. doi: 10.26442/00403660.2020.02.000569.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki T., Yoshida N., Nakabe N., et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77. doi: 10.1254/jphs.FP0071422.</mixed-citation><mixed-citation xml:lang="en">Suzuki T., Yoshida N., Nakabe N., et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77. doi: 10.1254/jphs.FP0071422.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Tarnawski A. S., Chai J., Pai R., Chiou S. K. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?. Dig Dis Sci. 2004;49(2):202-209. doi: 10.1023/b: ddas.0000017439.60943.5c.</mixed-citation><mixed-citation xml:lang="en">Tarnawski A. S., Chai J., Pai R., Chiou S. K. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?. Dig Dis Sci. 2004;49(2):202-209. doi: 10.1023/b: ddas.0000017439.60943.5c.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Markovic M., Zur M., Dahan A., Cvijić S. Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability. Eur J Pharm Sci. 2020;152:105440. doi: 10.1016/j.ejps.2020.105440.</mixed-citation><mixed-citation xml:lang="en">Markovic M., Zur M., Dahan A., Cvijić S. Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability. Eur J Pharm Sci. 2020;152:105440. doi: 10.1016/j.ejps.2020.105440.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Miyazaki K., Kishimoto H., Muratani M., Kobayashi H., Shirasaka Y., Inoue K. Mucins are Involved in the Intestinal Permeation of Lipophilic Drugs in the Proximal Region of Rat Small Intestine. Pharm Res. 2019;36(11):162. Published 2019 Sep 16. doi: 10.1007/s11095-019-2701-9.</mixed-citation><mixed-citation xml:lang="en">Miyazaki K., Kishimoto H., Muratani M., Kobayashi H., Shirasaka Y., Inoue K. Mucins are Involved in the Intestinal Permeation of Lipophilic Drugs in the Proximal Region of Rat Small Intestine. Pharm Res. 2019;36(11):162. Published 2019 Sep 16. doi: 10.1007/s11095-019-2701-9.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Joh T., Takezono Y., Oshima T., et al. The protective effect of rebamipide on paracellular permeability of rat gastric epithelial cells. Aliment Pharmacol Ther. 2003;18 Suppl 1:133-138. doi: 10.1046/j.1365-2036.18.s1.15.x.</mixed-citation><mixed-citation xml:lang="en">Joh T., Takezono Y., Oshima T., et al. The protective effect of rebamipide on paracellular permeability of rat gastric epithelial cells. Aliment Pharmacol Ther. 2003;18 Suppl 1:133-138. doi: 10.1046/j.1365-2036.18.s1.15.x.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Kurata S., Nakashima T., Osaki T., et al. Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J Clin Biochem Nutr. 2015;56(1):20-27. doi: 10.3164/jcbn.14-67.</mixed-citation><mixed-citation xml:lang="en">Kurata S., Nakashima T., Osaki T., et al. Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J Clin Biochem Nutr. 2015;56(1):20-27. doi: 10.3164/jcbn.14-67.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Kohata Y., Nakahara K., Tanigawa T., et al. Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett’s Esophagus in a Rat Model. Dig Dis Sci. 2015;60(9):2654-2661. doi: 10.1007/s10620-015-3662-4.</mixed-citation><mixed-citation xml:lang="en">Kohata Y., Nakahara K., Tanigawa T., et al. Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett’s Esophagus in a Rat Model. Dig Dis Sci. 2015;60(9):2654-2661. doi: 10.1007/s10620-015-3662-4.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
